Marinos Koulouroudias

Dr. Marinos Koulouroudias

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAli Ansaripour
Ali Ansaripour
Arian Arjomandi RadArian Arjomandi Rad
Arian Arjomandi Rad
MKMarinos Koulouroudias
Marinos Koulouroudias
DADimitrios C. Angouras
Dimitrios C. Angouras
Thanos AthanasiouThanos Athanasiou
Thanos Athanasiou
AKAntonios Kourliouros
Antonios Kourliouros
Background: Sarcopenia is a degenerative condition characterised by the loss of skeletal muscle mass and strength. Its impact on cardiac surgery outcomes remains poorly investigated. This meta-analysis aims to provide a comprehensive synthesis of the available evidence to determine the effect of sarcopenia on cardiac surgery outcomes. Methods: A systematic review and meta-analysis followed PRISMA guidelines from inception to April 2023 in EMBASE, MEDLINE, Cochrane database, and Google Scholar. Twelve studies involving 2717 patients undergoing cardiac surgery were included. Primary outcomes were early and late mortality; secondary outcomes included surgical time, infection rates, and functional outcomes. Statistical analyses were performed using appropriate methods. Results: Sarcopenic patients (906 patients) had a significantly higher risk of early mortality (OR: 2.40, 95% CI: 1.44 to 3.99, p = 0.0007) and late mortality (OR: 2.65, 95% CI: 1.57 to 4.48, p = 0.0003) compared to non-sarcopenic patients (1811 patients). There were no significant differences in overall surgical time or infection rates. However, sarcopenic patients had longer ICU stays, higher rates of renal dialysis, care home discharge, and longer intubation times. Conclusion: Sarcopenia significantly increases the risk of early and late mortality following cardiac surgery, and sarcopenic patients also experience poorer functional outcomes.

6 October 2016 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
AHAlice Hosking
Alice Hosking
MKMarinos Koulouroudias
Marinos Koulouroudias
FZFilip Zemrak
Filip Zemrak
JMJames C. Moon
James C. Moon
ARAlexia Rossi
Alexia Rossi
SPSteffen Petersen
Steffen Petersen
Adenosine can induce splenic vasoconstriction (splenic switch-off, SSO). In this study, we aim to evaluate the utility of identifying a lack of SSO for detecting false-negative adenosine stress perfusion cardiac magnetic resonance (CMR) scans. We visually analysed 492 adenosine stress perfusion CMR scans reported as negative in a cohort of patients with no previous history of coronary artery disease. A lack of SSO was identified in 11%. We quantified the phenomenon by drawing regions of interest on the spleen and comparing intensity between stress and rest scans, the spleen intensity ratio (SIR). Inter-rater agreement for qualitative determination of SSO was κ = 0.81 and inter-class correlation for quantitative determination of SSO was 0.94. The optimal threshold for SIR as an indicator of SSO was 0.40 (sensitivity = 82.5%, specificity = 92.3%, AUC = 0.91). 23 065 CMR scans and 9926 invasive coronary angiogram reports were retrospectively examined to identify patients with negative CMR scans who required coronary intervention in the subsequent 12 months (false negatives). We compared these scans with true positives who had positive adenosine stress perfusion CMR scans followed by coronary intervention. The rate of lack of SSO was 20.7% in the false-negative group versus 13.1% in true positives (P = 0.37). The lack of SSO is prevalent, easily measureable, and has potential to improve on haemodynamic criteria as a marker of adenosine understress in CMR perfusion scans.

31 January 2022 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
RARiccardo Giuseppe Abbasciano
Riccardo Giuseppe Abbasciano
MKMarinos Koulouroudias
Marinos Koulouroudias
TCThomas Chad
Thomas Chad
WMWalid Mohamed
Walid Mohamed
ILIrene Leeman
Irene Leeman
GMGavin James Murphy
Gavin James Murphy

29 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMarinos Koulouroudias
Marinos Koulouroudias
KVKonstantinos Velissarios
Konstantinos Velissarios
JKJohn Kokotsakis
John Kokotsakis
Dimitrios E. MagouliotisDimitrios E. Magouliotis
Dimitrios E. Magouliotis
PTPantelis Tsipas
Pantelis Tsipas
Thanos AthanasiouThanos Athanasiou
Thanos Athanasiou
The frozen elephant trunk is a formidable tool for the aortovascular surgeon. An appreciation of how to size the graft in different pathologies is key in achieving optimal results. Herein, we demonstrate worked examples of how imaging can be used to plan for a frozen elephant trunk and discuss the nuisances and uncertainties of sizing using three index cases: Type A aortic dissection, distal thoracic aortic aneurysm and chronic dissection.

16 April 2024 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MKMarinos Koulouroudias
Marinos Koulouroudias
MMMichele Di Mauro
Michele Di Mauro
GCGiovanni Chiariello
Giovanni Chiariello
PMPaolo Meani
Paolo Meani
RLRoberto Lorusso
Roberto Lorusso

13 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGiovanni Alfonso Chiariello
Giovanni Alfonso Chiariello
Michele Di MauroMichele Di Mauro
Michele Di Mauro
EVEmmanuel Villa
Emmanuel Villa
MKMarinos Koulouroudias
Marinos Koulouroudias
PBPiergiorgio Bruno
Piergiorgio Bruno
RLRoberto Lorusso
Roberto Lorusso
Background: In recent years, in case of aortic valve replacement (AVR), a significant increase in the use of bioprostheses has been observed. The Perceval sutureless bioprosthesis has proven to be safe and reliable in the short and mid-term, with limited but promising long-term results. An updated systematic review with the long-term results of patients who underwent a sutureless bioprosthesis implantation with a Perceval biological valve is herewith presented. Methods: Studies published between 2015 and 2024, including the long-term outcomes—with clinical as well as echocardiographic information for up to five years—of patients who underwent a Perceval implantation for AVR were selected from the published literature. The Cochrane GRADE system was used to assess the study quality, and the risk of bias in non-randomized studies (ROBINS-I) tool was used to evaluate studies. Results: Ten studies were selected with an overall number of 5221 patients. The long-term survival ranged from 64.8 to 87.9%, freedom from structural valve degeneration (SVD) from 96.1 to 100%, freedom from significant paravalvular leak from 98.5 to 100%, freedom from prosthetic endocarditis from 90.7 to 99%, and freedom from reintervention from 94 to 100%. The long-term mortality ranged from 6.5 to 27.4%. SVD was observed in 0–4.8% patients. Significant paravalvular leak was observed in 0–3.4% patients, and infective endocarditis was observed in 0–3.4%. A bioprosthesis-related reintervention at long-term follow-up was required for 0–4.3% of patients, and 1.7–7.1% of patients required a late new pacemaker implantation. The transprosthetic mean pressure gradient ranged from 9 to 14.7 mmHg, peak pressure gradient ranged from 17.8 to 26.5 mmHg, and EOA ranged from 1.5 to 1.7 cm2. Conclusions: This systematic review shows that there is still a paucity of data about sutureless bioprostheses. Nevertheless, the clinical results from prospective studies or retrospective series are encouraging. Medium- and long-term results seem to support the increasing use of this type of prosthesis.